In both murine tumor models used in our studies, the levels of tumor MHC Class I (~ 90%) and PD-L1 (Fig. 1a) in vivo are very similar within each treatment cohort, as is their capacity to mount an IFNγ response (Figs. 6 and 7). This evidence concerns the gene IFNG and neoplasm.